APIs, Excipients, and Manufacturing eBook
Read the article:
Predicting Tablet Potency in Continuous Manufacturing
Read the ebook:
Pharmaceutical Technology APIs, Excipients, and Manufacturing eBook
A modular toolbox enables residence time distribution-based control for continuous pharmaceutical manufacturing.
ANTON - STOCK.ADOBE.COM
In continuous pharmaceutical manufacturing, real-time assurance of critical quality attributes (CQAs) is highly desired. Among CQAs, control and assurance of tablet potency has been challenging due to lack of real-time measurement sensors tied to optimization programs. A modular self-contained toolbox developed using Python programming has been demonstrated to predict tablet potency based on a residence time distribution (RTD) model and apply a diversion strategy to divert out-of-specification tablets. The modular toolbox can be integrated with any commercially available tools to control tablet potency, can automatically calibrate the RTD model for different formulations and processes, and can be used to predict outlet concentrations, assuming accurately quantified inputs.
Read this article in Pharmaceutical Technology’s October 2021 APIs, Excipients, and Manufacturing eBook.
Read the article:
Predicting Tablet Potency in Continuous Manufacturing
Read the ebook:
Pharmaceutical Technology APIs, Excipients, and Manufacturing eBook
Ravendra Singh is Assistant Research Professor, NSF-ERC C-SOPS, Department of Chemical and Biochemical Engineering, Rutgers, The State University of New Jersey.
Pharmaceutical Technology
eBook: APIs, Excipients, and Manufacturing
October 2021
Pages: 44–49
When referring to this article, please cite it as R. Singh, “Predicting Tablet Potency in Continuous Manufacturing,” Pharmaceutical Technology APIs, Excipients, and Manufacturing eBook (October 2021).
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.